By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound ...

Tesla CEO Elon Musk calls for making weight loss drugs super low cost to improve American health, aligning with healthcare ...

Eli Lilly and Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors like alcohol abuse, smoking and drug addiction, Chief ...

Eli Lilly will launch studies to investigate whether its weight loss medications can help control addictive behaviors such as smoking and alcohol and drug abuse, CEO Dave Ricks revealed in a Dec. 10 ...

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 504.34% and ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...